Oral Lichen Planus Clinical Trial
Official title:
Comparative Evaluation of Effect of Oral Zinc Supplementation and Placebo as an Adjuvant to Topical Corticosteroid Therapy in Oral Lichen Planus Patients
Lichen planus is an auto-immune, chronic inflammatory disease that affects mucosal and
cutaneous tissue. Erosive and atrophic oral lichen planus (OLP) are difficult to manage
because patients present with symptoms ranging from episodic pain to severe discomfort and
they have the highest malignant transformation rate (MTR) amongst all the forms of OLP. Zinc
is associated with regeneration of epithelium, wound healing and mediating T-lymphocyte
function; all of which can lead to healing and re-epithelisation in the lesions of erosive
OLP. Besides this, it also has anti-oxidant and anti-inflammatory properties, which lead to
decrease in apoptosis and transformation into a malignant state.
This study intends to evaluate the effect of oral zinc supplements as an adjuvant to the
topical corticosteroid therapy in the treatment of OLP.
Lichen planus is a chronic muco-cutaneous disorder of the stratified squamous epithelium that
affects the oral and genital mucous membrane, skin, hair, nails and scalp.OLP is the mucosal
counterpart of cutaneous lichen planus.The disease was first described by Erasmus Wilson in
1866. The prevelance of disease in the Indian sub-continent is about 2.6%,with the mean age
being 30-60 years and with a female predilection. The cutaneous form is more persistent and
resistant to treatment while OLP is more frequent in occurrence.
OLP is a potentially pre-malignant oral epithelial lesion. It is a T-cell mediated
auto-immune disease in which the auto-cytotoxic CD8 + T cells trigger the apoptosis of the
basal cells of oral epithelium.OLP is an idiopathic disease, although there are certain
precipitating factors like HLA-A3, anxiety & stress, diabetes and hypertension.
OLP occurs bilaterally, the most common sites being buccal mucosa, tongue, lips, gingiva,
floor of mouth and palate. Wickham's striae are a pathogonomic feature. It has six clinical
presentations- Reticular, Erosive, Atrophic, Plaque-like, Papular and Bullous.The reticular
form is most common but its asymptomatic, while the erosive form is most severe with symptoms
ranging from mild burning to severe pain. The range of MTR for OLP is about 0-5%, with the
highest rate for erosive and atrophic types.Erosive OLP lesions arise as a complication of
the atrophic process after trauma or ulceration. Appear as a central area of erosion with
yellowish fibrinous exudate surrounded by erythema, with Wickham's striae in the periphery.
Atrophic OLP lesions appear bright red due to loss of epithelium.
A review study done on the recent concepts in the treatment of OLP concluded that
corticosteroids (mostly topical, rarely systemic) continue to be the mainstay of management
of OLP. However, there are some other drugs which have a significant contribution such as-
Calcineurin inhibitors (cyclosporine, tacrolimus, pimecrolimus), Retinoids, Dapsone,
Hydroxychloroquine, Mycophenolate mofetil and Enoxaprin. The non-pharmacological treatment
modalities include PUVA therapy, photodynamic therapy and laser therapy.
A recently conducted study found out that serum zinc levels were significantly decreased in
patients with erosive OLP in comparison with patients of non-erosive OLP, which may be
responsible for disintegration of epithelium in erosive OLP lesions.
The association of OLP and zinc lies in the fact that zinc is associated with the
regeneration of epithelium, enhancement of enzyme activity, contributes to protein structure,
helps in wound healing as well as inhibition and stimulation of lymphocyte reaction.The
deficiency of zinc also leads to compromised T-cell mediated immune defence.Zinc also has
anti-oxidant and anti-inflammatory properties, which can decrease apoptosis and
transformation to a malignant state.
Thus, the present study intends to evaluate the role of oral zinc supplementation as an
adjuvant to topical corticosteroid therapy on the treatment of oral lichen planus.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Not yet recruiting |
NCT06428630 -
Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus
|
Early Phase 1 | |
Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
Withdrawn |
NCT03836885 -
Apremilast - Oral Lichen Planus Trial
|
Phase 2 | |
Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 |